latest
develop
sever
infect
icu
could
summar
chang
epidemiolog
infect
pathogen
emerg
appear
new
resist
strain
especi
warridden
condit
upcom
new
antibiot
use
altern
rout
antibiot
administr
prolong
infus
antibiot
signific
chang
pattern
acut
infect
emerg
europ
recent
result
variou
factor
larg
number
refuge
middl
east
africa
elsewher
multidrugresist
mdr
tuberculosi
mdr
gramneg
bacteri
infect
includ
acinetobact
enter
mrsa
report
surveil
studi
throughout
europ
warridden
condit
led
reemerg
vaccineprevent
diseas
measl
poliomyel
well
crimean
congo
haemorrhag
fever
tickborn
viral
infect
casefat
ratio
widespread
balkan
region
autochthon
case
recent
report
spain
middl
east
respiratori
syndromecoronaviru
mer
cov
infect
import
europ
mortal
could
travelassoci
zika
viru
infect
detect
eu
countri
pregnant
women
sever
influenza
report
risk
factor
invas
pulmonari
aspergillosi
even
nonimmunocompromis
patient
although
candida
albican
still
singl
frequent
caus
fungaemia
icu
nonalbican
candida
respons
remark
epidemiolog
differ
europ
c
parapsilosi
frequent
southern
europ
c
glabrata
northern
europ
latter
acquir
echinocandin
resist
emerg
among
mdr
bacteri
infect
escherichia
coli
highest
resist
rate
broadspectrum
cephalosporin
southern
eastern
europ
via
extendedspectrum
betalactamas
klebsiella
pneumonia
highest
figur
come
greec
serbia
carbapenem
resist
e
coli
rare
europ
becom
preval
k
pneumonia
greec
itali
romania
less
eu
countri
three
main
carbapenemas
respons
resist
fig
isol
usual
sensit
colistin
fosfomycin
tigecyclin
although
resist
antibiot
also
rapidli
emerg
recent
describ
plasmidmedi
colistin
resist
gene
rare
found
human
isol
europ
clinic
signific
current
unknown
carbapenem
resist
report
isol
acinetobact
baumannii
portug
greec
itali
cypru
romania
bulgaria
isol
usual
coresist
aminoglycosid
quinolon
colistin
resist
baumannii
rare
tigecyclin
resist
may
occur
brief
exposur
drug
therapi
rapid
detect
resist
strain
essenti
effect
treatment
sever
phenotyp
genotyp
test
recent
describ
among
multiplex
andor
realtim
pcr
assay
dna
microarray
whole
genom
sequenc
malditof
mass
spectrometri
batch
biochem
test
provid
result
within
minut
coupl
hour
high
sensit
specif
biochem
test
would
requir
bacteria
cultur
first
clinic
specimen
genotyp
method
may
even
rapid
one
use
clinic
specimen
cultur
identifi
bacteria
also
detect
gene
antibiot
resist
sever
new
antibiot
avail
develop
includ
inhibitor
combin
ceftolozanetazobactam
ceftazidimeavibactam
ceftarolineavibactam
aztreonamavibactam
imipenem
relebactam
eravacyclin
novel
broadspectrum
fluorocyclin
broadspectrum
activ
plazomicin
nextgener
aminoglycosid
activ
mani
mdr
bacteria
new
quinolon
finafloxacin
avarofloxacin
zabofloxacin
nemonoxacin
delafloxacin
new
lipoglycopeptid
dalbavancin
oritavancin
new
oxazolidinon
tedizolid
potent
vitro
activ
linezolid
reviv
old
antibiot
fosfomycin
colistin
trimethoprimsulfamethoxazol
combin
tetracyclin
extendedspectrum
esbl
produc
mdr
gramneg
pathogen
mrsa
vre
alreadi
realiti
daili
clinic
practic
tabl
nebul
antibiot
use
adjunct
treatment
iv
rout
mdr
ventilatorassoci
pneumonia
vap
ventilatorassoci
tracheobronch
vat
aim
increas
antibiot
efficaci
deliv
high
dose
lung
reduc
drug
toxic
minim
risk
resist
current
avail
devic
jet
ultrason
vibrat
mesh
nebul
deliv
lung
parenchyma
antibiot
dose
place
chamber
sever
factor
physicochemicalpharmacolog
antibiot
properti
patient
paramet
variabl
ventil
circuit
paramet
import
order
maxim
antibiot
deliveri
reduc
residu
loss
drug
current
two
randomis
clinic
trial
mdrvap
treatment
nebul
antibiot
ongo
amikacin
inhal
program
bayer
iasi
program
cardea
pharma
former
program
usa
europ
includ
two
ident
superior
phase
iii
prospect
random
doubl
blind
placebocontrol
safeti
efficaci
trial
special
formul
amikacin
inhal
solut
use
combin
iv
therapi
power
demonstr
superior
standard
iv
therapi
onventil
handheld
pulmonari
drug
deliveri
system
pdd
iasi
program
cardea
pharma
includ
random
placebocontrol
studi
adjunct
iv
antibiot
use
special
formul
amikacin
mg
fosfomycin
mg
inhal
solut
eflow
inlin
nebul
system
pari
eflow
techolog
aim
improv
outcom
mdr
vap
shorten
ventil
day
howev
studi
adjunct
aerosol
therapi
compar
standard
care
iv
antibiot
patient
gramneg
vap
ineffect
improv
clinic
outcom
despit
reduc
bacteri
burden
today
modern
approach
treatment
antibiot
critic
ill
patient
base
adequ
exposur
accord
pkpd
properti
aim
person
dose
prolong
continu
infus
mainli
variou
betalactam
treatment
approach
aim
reduc
mortal
infect
patient
increas
efficaci
antibiot
overcom
potenti
resist
minim
toxic
associ
antibiot
conclus
although
sever
new
emerg
reemerg
infect
pose
threat
icu
patient
new
diagnost
therapeut
option
avail
counter
howev
yet
see
impact
eagerli
await
result
ongo
trial
